Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia

Fig. 6

Survival probability by different treatments after CR1 in patients with MRD < 0.1% before consolidation. EFS (a), OS (b), and CIR (c) of the patients who underwent HSCT during CR1 and those who only received consolidation chemotherapy. CR1, the first complete remission; EFS, event-free survival; OS, overall survival; CIR, cumulative incidence of relapse; MFC, multiparametric flow cytometry; MRD, minimal residual disease

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us